BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu Y, Fung S, Gane EJ, Dinh P, Flaherty JF, Svarovskaia ES, Miller MD, Kitrinos KM. Evaluation of HBV DNA decay kinetics in patients containing both rtM204V/I mutant and wild-type HBV subpopulations during tenofovir DF (TDF) monotherapy or combination therapy with emtricitabine (FTC)/TDF. J Med Virol 2014;86:1473-81. [PMID: 24861361 DOI: 10.1002/jmv.23982] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Jiang D, Wang J, Zhao X, Li Y, Zhang Q, Song C, Zeng H, Wang X. Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistance. Liver Int 2020;40:83-91. [PMID: 31498528 DOI: 10.1111/liv.14241] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
2 Sun D, Zhu L, Yao D, Chen L, Fu L, Ouyang L. Recent progress in potential anti-hepatitis B virus agents: Structural and pharmacological perspectives. European Journal of Medicinal Chemistry 2018;147:205-17. [DOI: 10.1016/j.ejmech.2018.02.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
3 Lok AS, Ganova-Raeva L, Cloonan Y, Punkova L, Lin HS, Lee WM, Ghany MG; Hepatitis B Research Network (HBRN). Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment. J Viral Hepat 2017;24:1032-42. [PMID: 28581155 DOI: 10.1111/jvh.12732] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
4 Huang YS, Chang SY, Sheng WH, Sun HY, Lee KY, Chuang YC, Su YC, Liu WC, Hung CC, Chang SC. Virological Response to Tenofovir Disoproxil Fumarate in HIV-Positive Patients with Lamivudine-Resistant Hepatitis B Virus Coinfection in an Area Hyperendemic for Hepatitis B Virus Infection. PLoS One 2016;11:e0169228. [PMID: 28033344 DOI: 10.1371/journal.pone.0169228] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
5 Şahin E. Evaluation of antiviral resistant hepatitis B virus subpopulations in patients with chronic hepatitis B by using terminal restriction fragment length polymorphism. Virusdisease 2015;26:267-75. [PMID: 26645037 DOI: 10.1007/s13337-015-0282-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Soriano V, Labarga P, de Mendoza C, Peña JM, Fernández-montero JV, Benítez L, Esposito I, Barreiro P. Emerging Challenges in Managing Hepatitis B in HIV Patients. Curr HIV/AIDS Rep 2015;12:344-52. [DOI: 10.1007/s11904-015-0275-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
7 Soriano V, de Mendoza C, Peña JM, Barreiro P. Advances in treating drug-resistant hepatitis B virus in HIV-infected patients. Expert Opin Pharmacother 2015;16:179-86. [PMID: 25529507 DOI: 10.1517/14656566.2015.973852] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]